Lentiviral vectors have become the center of attention for its use as gene transfer vectors in gene therapy. Here, we have developed a new lentiviral production system for the clinical grade production of Lentiviral vectors on a large-scale serum-free suspension platform. This technology employs a newly developed propriety set of GMP reagents comprising of culture media, suspension cells, transfection reagent and boosting enhancers. With new culture media and media supplement, high density cell growth is optimized for maximum LVVs production. Customized lentivirus transfection reagents ensure highly efficient plasmids delivery. LVVs production is further elevated by the boosting enhancers. Taken together, our innovative system is able to deliver >2-3.0E+08 (TU/mL) functional titer with un-concentrated LVVs. We demonstrate that this system can be linearly adapted to bioreactors and wavebags system for large scale LVVs production without compromising the virus yield, which is ideal for industrial needs of gene therapy.